Rayence Co., Ltd.

Rayence Co., Ltd.

KKRX:228850
8,020.00
KRW
+110.00
(+1.39%)
263.11EPS
22.73P/E
95.36BMarket Cap
Nov 16Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6,202.38
6,877.76
6,296.89
6,607.17
7,200.23
8,014.86
6,465.17
8,553.46
9,350.68
9,089.83
7,986.48
7,298.77
8,379.29
Basic EPS, GAAP
256
1,150
943
907
973
933
-122
919
1,401
1,246
498
-336
266.64
Free Cash Flow per Basic Share
-4.43
-70.3
-440.55
672.26
419.37
-440.43
972.46
1,191.89
933.23
1,365.45
1,048.02
437.02
283.79
Dividend per Share
- -
- -
- -
105.83
100.13
99.96
164.21
100.02
99.99
163.93
100.09
100.12
- -
Book Value per Share
3,662.05
4,766.75
10,149.52
10,913.02
11,556.9
12,346.92
11,957.43
12,745.95
14,281.99
15,265.3
15,530.61
15,057.86
15,357.18
Tangible Book Value per Share
3,306.87
4,007.54
9,026.78
9,651.79
10,333.77
10,907.48
10,786.85
12,112.57
13,873.86
14,837.19
15,027.26
14,571.68
14,864.68
Basic Weighted Avg Shares
13
13
16
16
16
16
16
16
16
16
16
16
16
Sales/Revenue/Turnover
77,943
86,609
98,457
106,518
116,389
126,175
101,524
134,568
147,161
142,986
125,564
114,723
131,693
Operating Margin (%)
14.2
22.8
18.26
16.24
18.23
18.1
8.31
17.89
17.23
13.77
5.28
-3.44
3.18
Depreciation Expense
3,891
3,732
5,178
6,232
6,897
7,659
8,043
6,673
4,954
4,123
5,335
4,773
3,825
Net Income, GAAP
3,217
14,482
14,745
14,622
15,728
14,688
-1,916
14,458
22,049
19,600
7,830
-5,281
4,191
Effective Tax Rate (%)
21.31
19.24
18.06
3.24
28.76
34.25
- -
30.63
13.51
17.27
36.48
- -
49.73
Profit Margin (%)
4.13
16.72
14.98
13.73
13.51
11.64
-1.89
10.74
14.98
13.71
6.24
-4.6
3.18
Working Capital
18,350
25,009
115,613
123,002
130,515
146,311
148,488
157,009
187,619
206,749
212,751
205,683
209,048
LT Debt
6,868
4,501
2,082
472
- -
9,681
10,722
646
396
1,148
2,579
2,763
3,240
Total Equity
46,109
60,018
166,048
176,983
182,327
194,275
187,538
199,578
225,498
240,798
244,668
237,366
242,100
Return on Invested Capital (%)
- -
22.01
11.47
9.31
8.1
7.44
- -
7.83
9.71
6.86
1.72
- -
0.85
Return on Capital (%)
- -
21.01
12.06
8.66
8.78
8.05
- -
7.38
10.37
8.78
3.4
- -
1.78
Return on Common Equity (%)
- -
27.29
13.08
8.55
8.77
7.81
-1
7.44
10.37
8.43
3.23
-2.19
1.73

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,915
2,309
2,179
LT Borrowings
- -
- -
- -
LT Finance Leases
2,763
3,515
3,240
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
16
16
16
Market Capitalization
81,829
95,678
95,363

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
220,427
228,816
228,062
Cash, Cash Equivalents & STI
151,524
151,652
147,156
Accounts Receivable, Net
29,819
37,645
40,473
Inventories
34,257
32,981
34,028
Total Current Liabilities
14,743
20,915
19,014
Payables & Accruals
- -
- -
- -
ST Debt
1,915
2,309
2,179
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.42%
4.96%
-2.98%
Free Cash Flow
-17.34%
-6.85%
-58.31%
Net Income, GAAP
-115.19%
-208.16%
-167.45%
Sales/Revenue/Turnover
3.83%
3.65%
-8.63%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
35,724
32,939
31,098
25,803
125,564
2025
27,247
28,993
29,349
29,135
114,723
2026
36,751
36,458
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
277
178
102
-59.31
498
2025
14
-80
157.07
-426.4
-336
2026
374.45
162
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
100.09
2025
- -
- -
- -
- -
100.12
2026
- -
- -
- -
- -
- -

Company Description

CEO
Young-Gwon Seo
Full Time Employees
225
Sector
Health technology
Industry
Medical specialties
Address
Hwaseong-si South Korea
IPO Date
Apr 11, 2016
Business
Rayence Co., Ltd. is a South Korea-based medical and industrial imaging technology company that specializes in the design, development, and manufacture of digital X-ray flat panel detectors, intraoral sensors, and comprehensive radiographic imaging solutions. Founded in 2011 and headquartered in Hwaseong-si, Gyeonggi-do, South Korea, the company operates as a key imaging subsidiary of Vatech Co., Ltd. Rayence delivers core digital radiography components and complete imaging systems across healthcare, dental, veterinary, and industrial inspection sectors globally. The company's product and service portfolio is organized into distinct specialized divisions: Medical Digital Radiography Detectors, comprising amorphous silicon thin-film transistor (a-Si TFT) and complementary metal-oxide-semiconductor (CMOS) flat panel detectors designed for general radiography, portable diagnostic carts, mammography, and surgical C-arm systems; Dental Imaging Solutions, including high-resolution intraoral sensors under the EzSensor series, panoramic and cephalometric CMOS sensor modules, and specialized cone-beam computed tomography (CBCT) detection components; Veterinary Imaging Systems, marketed under the MyVet brand, offering dedicated small-animal and equine digital radiography tables, portable X-ray units, specialized veterinary dental imaging sensors, and small-animal 3D CT diagnostic systems; Industrial and Non-Destructive Testing (NDT) Detectors, featuring ultra-high-resolution, radiation-hardened CMOS and dynamic flat panel detectors engineered for electronic component inspection, semiconductor packaging, printed circuit board (PCB) assembly verification, and electric vehicle (EV) secondary battery cell defect analysis; and Proprietary Imaging Software, including the Xmaru software suite for radiographic image acquisition, advanced filtering algorithms, calibration, picture archiving and communication systems (PACS) integration, and veterinary-specific diagnostic workflow management. Rayence maintains direct business operations, research and development facilities, and manufacturing infrastructure in South Korea, complemented by international sales, customer service, and distribution subsidiaries in the United States (Rayence Inc. and MyVet Imaging Inc.), Europe, China, and Latin America. The company serves original equipment manufacturers (OEMs), medical device system integrators, dental equipment suppliers, veterinary clinics, hospitals, and industrial inspection equipment manufacturers across North America, Europe, Asia-Pacific, Latin America, and the Middle East. In recent developments, Rayence has accelerated its strategic expansion into high-growth non-destructive industrial testing and specialized clinical segments. The company has broadened its industrial portfolio with the commercial release of high-durability, high-speed CMOS detectors optimized for in-line quality inspection of cylindrical and pouch-type secondary batteries used in electric vehicles. In its healthcare and dental divisions, Rayence has introduced next-generation indium gallium zinc oxide (IGZO) oxide TFT and curved CMOS detector architectures that provide enhanced low-dose sensitivity, higher frame rates for real-time fluoroscopy, and reduced distortion in compact diagnostic environments. Additionally, Rayence has expanded its MyVet brand footprint through strategic distribution partnerships with multinational veterinary hospital networks and diagnostic equipment distributors, while advancing cloud-enabled imaging workflows and automated diagnostic assistance tools across its software platforms.